Scientific Leadership Group Core

点击翻译按钮获取中文摘要

PROJECT SUMMARY The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) fills a unique role among the NIH- funded networks by bringing together scientific and clinical investigators with the requisite knowledge and experience to design and implement interdisciplinary, developmentally appropriate prevention strategies for youth living with HIV and those at-risk in the United States (US). An experienced, multidisciplinary, and visionary Scientific Leadership Group (SLG) is needed who is poised to develop, refine, and support both an established and emerging ATN scientific agenda that impacts the HIV epidemic among youth domestically. Seamless collaboration will be essential at all levels, expecting and requiring innovation from investigators invested in addressing the significant challenges and seizing opportunities within the field of adolescent HIV prevention and care research. Efficient and effective communication strategies to accomplish high-impact research obligates synergies between the ATN SLG and Scientific Leadership Center (SLC), the Statistical and Data Management Core (SDMC), the Operations and Collaborations Center (OCC), the Research Project teams, Site Consortiums and NIH and industry partners. The SLG, working collaboratively with the SLC, SDMC, OCC and NIH is poised to actuate the unique mission, strengths, and expertise housed within the ATN, to identify gaps in the ATN research portfolio, and to form additional strategic partnerships that ensure the ATN’s swift response to high priority and emergent research areas. Given the broad ATN agenda, we have formulated a strong, interdisciplinary SLG which includes the world’s experts in all areas relevant to ending the HIV epidemic among adolescents in the US. This team consists of investigators with diverse expertise and experiences, including diversity in terms of race/ethnicity, sexual and gender identity, HIV-status, geography, discipline, and training. Building upon years of collective experience, Drs. Hightow-Weidman and Hosek will provide the necessary leadership and infrastructure to support the SLG to develop and refine the research agenda of the ATN, convene working groups as needed, prioritize emerging research projects, efficiently manage the development of clinical protocols, implement, and complete clinical trials and ensure timely publication and communication of results. Drs. Hightow-Weidman and Hosek aim to use an approach toward management of the SLG, honed through decades of prior ATN and clinical trials experiences, that will foster innovation and effectiveness through flexibility, open communication between all SLG team members, mutual respect, collective problem solving, and shared accountability. The SLG is configured through Leadership Teams organized around six areas: Biomedical Therapeutics, Comorbidities and Coinfections, Laboratory, Diagnostics and Mobile Technologies, Institutions, Organizations and Policy, Equity, Inclusion, and Engagement, and Risk and Resilience, and supported by a Bioethics Committee. These content areas encompass the areas of focus required to truly catalyze multidisciplinary research and translate the findings to ensure maximum clinical and policy impact by the ATN.